They just dont seem like the kind of company that would invest in hiring an internal PR team, or pay a premium for an external PR service to achieve the marketing media excitement we're discussing.
they seriously seem like health professionals, scientists and project managers dedicated to producing clinical outcomes. And maybe that's is not a bad thing. Sometimes the work will speak for itself.
if NEU is under the radar, it means i can accumulate for longer, i can continue to buy shares at this rate right up until trial readouts. And if the results show efficacy, then the share price will reflect that, its what happened for Trof, it will happen again with 2591. Preferably with low shorts, and little to no sentiment dramas that we might see when something is overhyped and shareholders expect too much.
They just dont seem like the kind of company that would invest...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
-0.310(1.54%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.45 | $19.74 | $4.663M | 234.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 507 | $19.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.89 | 765 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |